tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Savara (SVRA) and Ventyx Biosciences (VTYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Quantum-Si (QSIResearch Report), Savara (SVRAResearch Report) and Ventyx Biosciences (VTYXResearch Report).

Quantum-Si (QSI)

Canaccord Genuity analyst Kyle Mikson CFA maintained a Hold rating on Quantum-Si on May 10 and set a price target of $1.50. The company’s shares closed last Friday at $1.70.

According to TipRanks.com, CFA has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.8% and a 21.9% success rate. CFA covers the Healthcare sector, focusing on stocks such as Pacific Biosciences, Castle Biosciences, and Lucid Diagnostics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quantum-Si with a $2.75 average price target.

See today’s best-performing stocks on TipRanks >>

Savara (SVRA)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Savara, with a price target of $6.00. The company’s shares closed last Friday at $4.66.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 11.2% and a 45.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and KalVista Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Savara with a $9.30 average price target, which is an 89.4% upside from current levels. In a report issued on May 6, Oppenheimer also maintained a Buy rating on the stock with a $9.50 price target.

Ventyx Biosciences (VTYX)

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Ventyx Biosciences yesterday and set a price target of $15.00. The company’s shares closed last Friday at $4.09, close to its 52-week low of $1.87.

According to TipRanks.com, Nash is a 3-star analyst with an average return of 1.9% and a 37.7% success rate. Nash covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Madrigal Pharmaceuticals, and Cardiol Therapeutics.

Ventyx Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $11.71, a 141.9% upside from current levels. In a report issued on May 9, Wells Fargo also maintained a Buy rating on the stock with a $16.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on QSI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles